Simultaneous tDCS and Computerised Gamified Short-term Memory Task Feasibility — ACTTDCS-FG  

Genetic Predisposition Clinical Trial

Official title: Effects of Transcranial Direct Current Brain Stimulation on Apolipoprotein-ε4 Allele Gene Carriers on an App-based Short-term Memory Task

Status Completed

Clinical Trial Summary

The goal of this observational study is to gain insight into the effects of transcranial direct current stimulation (tDCS) on short-term memory task performance and the feasibility of tDCS in overtly healthy carriers of the susceptibility allele, Apolipoprotein (APOE) ε4, for late-onset Alzheimers disease. The main questions the study aims to answer are: - If tDCS is feasible in overtly healthy APOE ε4 carriers using a headset and an app-based short-term memory task. - If overtly healthy APOE ε4 carriers perform better on a complex short-term memory task when receiving tDCS to the right hemisphere (F4 à PZ) compared to the left hemisphere (F3 à PZ) or sham tDCS. Participants will be asked to complete an app-based short-term memory task while receiving either tDCS to either the right or left hemisphere or sham stimulation on 3 different days spread out over 1-3 weeks.

Clinical Trial Description

Alzheimer's disease (AD) is the most common neurodegenerative disorder causing dementia. The most common form of AD is that of idiopathic AD, or late-onset AD, which typically affects individuals above the age of 65. Individuals, who are carriers of the Apolipoprotein (APOE) ε4 allele have an increased risk of developing late-onset AD, and AD brain pathology has been observed in APOE ε4 carriers as young as 55 years of age. AD can be perceived as a continuum, with the pathophysiological disease process beginning in the brain many years prior to the onset of overt symptoms. Thus, individuals may show evidence of AD biomarkers in blood or cerebrospinal fluid or on brain scans in the absence of any overt symptoms. Individuals with incipient AD brain pathology but no overt symptoms may be classified as 'preclinical AD'. APOE ε4 allele carriage increases the risk of developing AD brain pathology 2-4 fold. One of the most common cognitive symptoms in AD is memory impairment, such as impairments in short-term memory (STM). Subtle impairments in memory, including in STM, can even be detected in preclinical AD using sensitive memory tests. Therefore, STM may provide a suitable target to help preserve individual's cognitive functioning earlier in the disease process. Cognitive reserve is a hypothetical construct proposed to explain the incongruency between the burden of AD pathology and cognitive dysfunction observed in some older individuals and has been defined as the ability to optimise or maximise performance through differential recruitment of brain networks. Epidemiological studies suggest that the cognitive reserve is increased by lifetime exposures, including educational and occupational attainment as well as leisure activities in late life. An underlying assumption is that these exposures improve brain plasticity. Cognitive training has shown positive effects with regards to promoting brain plasticity in older adults and could thus have the potential to foster or strengthen cognitive reserve in individuals at risk for developing AD later in life. Cognitive training in combination with other neuroplasticity-enhancing techniques has been suggested as an option for promoting the positive effects of cognitive training alone. Transcranial direct current stimulation (tDCS) is a noninvasive neuro-modulatory technique where low intensity direct current is delivered to cortical areas to facilitate or inhibit ongoing, spontaneous neuronal activity. As tDCS has been shown to improve STM in healthy elderly participants, combining cognitive training with tDCS may be a way to enhance the effects of cognitive training and enhance cognitive reserve. Thus, it is sensible to explore the feasibility of tDCS on improving STM during a computerised game targeting STM, starting with healthy elderly APOE ε4 allele carriers, i.e. healthy elderly individuals, who are genetically predispositioned to AD, but who are otherwise healthy. This study aims to investigate the effect of tDCS on memory performance on an app-based STM task in healthy elderly APOE ε4 carriers aged 55-75. All participants will be recruited from an existing in-house registry of individuals who have already been confirmed to be APOE ε4 carriers on a blood test. The tDCS or sham stimulation will be delivered by a headseat, where the spatial arrangement of the electrodes that delivers the stimulation and their outlets used in the stimulation determines the regions and distributed networks of the brain being stimulated. Participants will first try out the app-based STM task on its own in order to become familiar with it. Thereafter, they will come in on 3 different days within 1-3 weeks, where they will complete the same STM task again while undergoing either active or sham tDCS. This will allow for the examination of whether active tDCS can improve memory performance on this type of complex STM task in overall healthy elderly individuals who are genetically predisposed for late-onset AD. ;

Related Conditions & MeSH terms

• Genetic Predisposition
• Genetic Predisposition to Disease

• NCT number: NCT06402266
• Study type: Observational
• Source: University of Aarhus
• Status: Completed
• Start date: July 4, 2022
• Completion date: November 23, 2023